Activity of antimicrobial combinations against KPC-2-producing Klebsiella pneumoniae in a rat model and time-kill assay

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4301-4304

  Toledo, Paula Virginia Michelon ^a,b   Aranha, Ayrton Alves ^a,b   Arend, Lavinia Nery ^c   Ribeiro, Vanessa ^d   Zavascki, Alexandre Prehn ^d   Tuon, Felipe Francisco ^a,e  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b STATE UNIVERSITY OF PONTA GROSSA   (Brazil)

^c Bacteriology Section   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^e HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE KPC-2; DRUG COMBINATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE; TREATMENT OUTCOME; ANIMAL; ASCITES FLUID; BACTERIAL COUNT; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GENETICS; KAPLAN MEIER METHOD; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MORTALITY; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ASCITIC FLUID; BETA-LACTAMASES; COLONY COUNT, MICROBIAL; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUG SYNERGISM; FEMALE; KAPLAN-MEIER ESTIMATE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, WISTAR;

EID: 84931282008     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00323-15     Document Type: Article

References (28)

1. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 9:228-236. http://dx.doi.org/10.1016/S1473-3099(09)70054-4.
2. Toledo PV, Arend LN, Pilonetto M, Costa Oliveira JC, Luhm KR, Working Group in Healthcare Associated Infections. 2012. Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil. J Hosp Infect 80:351-353. http://dx.doi.org/10.1016/j.jhin.2012.01.010.
3. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 30: 1180-1185. http://dx.doi.org/10.1086/648451.
4. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
5. Hirsch EB, Tam VH. 2010. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrugresistant infection. J Antimicrob Chemother 65:1119-1125. http://dx.doi.org/10.1093/jac/dkq108.
6. Tuon FF, Rocha JL, Toledo P, Arend LN, Dias CH, Leite TM, Penteado- Filho SR, Pilonetto M, Zavascki AP. 2012. Risk factors for KPCproducing Klebsiella pneumoniae bacteremia. Braz J Infect Dis 16:416-419. http://dx.doi.org/10.1016/j.bjid.2012.08.006.
7. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113. http://dx.doi.org/10.1128/AAC.06268-11.
8. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapen-emase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. http://dx.doi.org/10.1128/AAC.02166-13.
9. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. 2011. Predictors of mortality in patients with bloodstream infections caused by KPCproducing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 17:1798-1803. http://dx.doi.org/10.1111/j.1469-0691.2011.03514.x.
10. Zavascki AP, Bulitta JB, Landersdorfer CB. 2013. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11:1333-1353. http://dx.doi.org/10.1586/14787210.2013.845523.
11. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L. 2014. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305-2309. http://dx.doi.org/10.1093/jac/dku168.
12. rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G. 2013. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect 19:141-160. http://dx.doi.org/10.1111/j.1469-0691.2011.03703.x.
14. Toledo PV, Tuon FF, Bail L, Manente F, Arruda P, Aranha-Junior AA. 2014. Experimental model for treatment of extended spectrum betalactamase producing-Klebsiella pneumoniae. Arq Bras Cir Dig 27:168-171. http://dx.doi.org/10.1590/S0102-67202014000300002.
15. Murphy TM, Deitz JM, Petersen PJ, Mikels SM, Weiss WJ. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 44:3022-3027. http://dx.doi.org/10.1128/AAC.44.11.3022-3027.2000.
16. Nannini EC, Pai SR, Singh KV, Murray BE. 2003. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 47:529-532. http://dx.doi.org/10.1128/AAC.47.2.529-532.2003.
17. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. 2012. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 56:5724-5727. http://dx.doi.org/10.1128/AAC.01333-12.
18. Chang YL, Chou MH, Lin MF, Chen CF, Tsai TH. 2002. Determination and pharmacokinetic study of meropenem in rat bile using on-line microdialysis and liquid chromatography. J Chromatogr A 961:119-124. http: //dx.doi.org/10.1016/S0021-9673(02)00078-X.
19. Mimoz O, Leotard S, Jacolot A, Padoin C, Louchahi K, Petitjean O, Nordamnn P. 2000. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenemhydrolyzing beta-lactamase-producing strain of Enterobacter cloacae. Antimicrob Agents Chemother 44:885-890. http://dx.doi.org/10.1128/AAC.44.4.885-890.2000.
20. Toledo PV, Tuon FF, Arend L, Aranha Junior AA. 2014. Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis. Braz J Infect Dis 18:574-575. http://dx.doi.org/10.1016/j.bjid.2014.05.003.
21. Pournaras S, Vrioni G, Neou E, Dendrinos J, Dimitroulia E, Poulou A, Tsakris A. 2011. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 37:244-247. http://dx.doi.org/10.1016/j.ijantimicag.2010.10.031.
22. Michail G, Labrou M, Pitiriga V, Manousaka S, Sakellaridis N, Tsakris A, Pournaras S. 2013. Activity of tigecycline in combination with colistin, meropenem, rifampin, or gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother 57:6028-6033. http://dx.doi.org/10.1128/AAC.00891-13.
23. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 34:8.e1-8.e9. http://dx.doi.org/10.1016/j.ijantimicag.2008.11.006.
24. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, Canton R. 2008. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamaseproducing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 60:319-322. http://dx.doi.org/10.1016/j.diagmicrobio.2007.09.017.
25. Yahav D, Lador A, Paul M, Leibovici L. 2011. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66:1963-1971. http://dx.doi.org/10.1093/jac/dkr242.
26. Sanchez-Romero MA, Casadesus J. 2014. Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proc Natl Acad Sci U S A 111:355-360. http://dx.doi.org/10.1073/pnas.1316084111.
27. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. 2011. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 55:1420-1427. http://dx.doi.org/10.1128/AAC.01253-10.
28. Hagihara M, Housman ST, Nicolau DP, Kuti JL. 2014. In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 58:874-879. http://dx.doi.org/10.1128/AAC.01624-13.